Compare ResMed Inc. (RMD) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs ThredUp Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while ThredUp Inc trades at $2.73 (market cap $350.00M). The key difference: ResMed Inc. is far larger — about 91.1× ThredUp Inc's market cap, and ResMed Inc. pays a 1.19% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| RMD | TDUP | |
|---|---|---|
Market Cap | $31.89B | $350.00M |
Sector | Health | Consumer Cyclical |
52-Week High | $283.28 | $10.92 |
52-Week Low | $182.82 | $2.52 |
Enterprise Value | $31.24B | $348.18M |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
ThredUp (TDUP) trades at $2.67, down 1.84% on the day, amid a bearish technical signal. The company reported a Q2 2026 GAAP loss of $0.05 per share, missing the expected $0.03 loss, and cut its full-year revenue outlook, citing promotional headwinds. Despite a high gross margin of 79.52%, the firm remains unprofitable with a net income margin of -6.65%. Recent news includes participation in investor conferences and the launch of a peer-to-peer marketplace, but also multiple law firm investigations into securities claims following the earnings miss.
The outlook is clouded by persistent losses and competitive pressures, though analyst consensus leans Buy (57% of 14 analysts). Key risks include execution on profitability, the sustainability of revenue growth, and potential legal overhangs. The stock's trajectory hinges on demonstrating a clear path to net income positivity amid a challenging retail environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
